RIEM News LogoRIEM News

Multiply Labs reduces biomanufacturing costs by 74% with UR cobots - The Robot Report

Multiply Labs reduces biomanufacturing costs by 74% with UR cobots - The Robot Report
Source: roboticsbusinessreview
Author: @therobotreport
Published: 8/21/2025

To read the full content, please visit the original article.

Read original article
Multiply Labs Inc. has developed an innovative “robotic biomanufacturing cluster” using Universal Robots (UR) collaborative robots (cobots) to automate the production of personalized cell therapies, significantly reducing manufacturing costs by 74%. These therapies, often used to treat blood cancers like lymphoma and leukemia, are traditionally expensive—ranging from $300,000 to $2 million per dose—due to their highly customized nature and manual, artisanal production processes. Multiply Labs’ automated system, controlled via the cloud, replicates complex manual tasks with high precision, repeatability, and in sterile conditions, addressing challenges such as contamination risks and scalability. The company selected UR cobots for their six-axis capabilities, delicate force control, software integration, and cleanroom compatibility. Multiple UR cobots operate in parallel with collision avoidance, enabling the full manufacturing workflow to be automated. This collaboration marks UR’s first partnership in the cell and gene therapy sector and demonstrates how robotics can enhance pharmaceutical manufacturing efficiency and broaden patient

Tags

robotcobotsbiomanufacturingcell-therapypharmaceutical-manufacturingautomationcollaborative-robots